IMPDH1
Inosine-5'-monophosphate dehydrogenase 1
As of the edition of 20 October 2026, IMPDH1 (inosine-5'-monophosphate dehydrogenase 1, UniProt P20839) has 7 drugs tested at it and 11 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P20839
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 18
- Disease areas
- Infections; Digestive system; Immune system; Blood and lymph; Cancer; Urinary and reproductive; Pregnancy and women's health; Heart and blood vessels
- Registered trials of its drugs
- 1,550
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ribavirin | Marketed | Phase 4 | none listed |
| Mycophenolate mofetil | Marketed | Phase 4 | none listed |
| Mycophenolic acid | Marketed | Phase 4 | none listed |
| Thioguanine | Marketed | Phase 4 | none listed |
| Mizoribine | Active | Phase 4 | none listed |
| AVN-944 | Stopped | Phase 2 | none listed |
| Merimepodib | Went quiet | Phase 2 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Engaged | 5 |
| Undetermined | 3 |
| Total on the list | 11 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Vertex | Route A |
| Bausch Health | Route B |
The other 8 companies at IMPDH1
In the product11 companies in all; 8 are not named here, and no score is.
See the 11 companies at IMPDH1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.